Market Forecast
Showing 1–12 of 16 results
-
Adrenoleukodystrophy (ALD) | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Adrenoleukodystrophy (ALD) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Allergic Conjuctivitis (AC) | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Allergic Conjuctivitis (AC) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Alpha Antitrypsin Deficiency (AATD)| Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Alpha Antitrypsin Deficiency (AATD) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Celiac Disease (CD) | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Celiac Disease (CD) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Eosinophilic Esophagitis (EoE)| Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Eosinophilic Esophagitis (EoE) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Genital Herpes | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Genital Herpes report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Hemophilia A Gene Therapy- Key opinion leaders (KOLs) Insight- An Executive Report 2020
$6,250.00 – $16,750.00Hemophilia A Gene Therapy- Key opinion leaders (KOLs) Insight- An Executive Report 2020 Deck provides a competitive advantage towards understanding the current gene therapy challenges, safety and efficacy concerns, hemophilia A gene therapy market uptake, Gene therapy competition, Hem A gene therapy re-dosing, Patients switching to gene therapy from hemlibra and factor replacement therapies and other critical key intelligent questions through 14 in-depth interviews with leading US and European KOLs.
-
Herpes Simplex Virus (HSV) Infections | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Herpes Simplex Virus Infections report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
High grade intraepithelial lesion (HSIL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00 Select options -
KRAS inhibitors-Market opportunity, Epidemiology & Market Forecast, Pipeline and Competitive Analysis, 2020-2030
$3,250.00 – $9,750.00This KRAS report covers the KRAS market opportunity providing key competitive analysis, 37 companies with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.
-
Multiple Sclerosis | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Multiple Sclerosis report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Narcolepsy | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00The Narcolepsy report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.